Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia

Karapanagiotidis, Georgios T.; Antonitsis, Polychronis; Charokopos, Nikolaos; Foroulis, Christophoros N.; Anastasiadis, Kyriakos; Rouska, Efthymia; Argiriadou, Helena; Rammos, Kyriakos St.; Papakonstantinou, Christos

doi:10.1186/1749-8090-4-59

Cited by 39 publications

(45 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, only the MMP-9 serum level in the control group showed a weak positive correlation with age (correlation coefficient=0.375; P=0.016). Consistent with other studies, there were no significant differences in serum marker levels between men and women in the control group 29,41 .…”

Section: Discussionsupporting

confidence: 92%

“…Many different studies have investigated the serum levels of MMP-2, MMP-9 and VEGF in cancer patients with different and sometimes contradictory results 8,[24][25][26][27][28][29][30][31][32] . We wanted to incorporate these arguable markers into specific clinical events of two narrowly defined groups of cancer patients to prove or disprove their clinical utility.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

Škereňová¹,

Mikulová²,

Čapoun³

et al. 2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background and Aims. Metastases are a severe complication in cancer patients and biomarkers predicting their progression are still lacking for specific groups of patients. HER2 positive breast cancer (HER2 BC) patients on trastuzumab therapy are at risk of the development of unpredictable and often fatal central nervous system (CNS) metastases and castration resistant prostate cancer (CRPC) patients urgently need a marker of disease progression during therapy. Proposed metastatic markers: circulating tumor cells (CTC), serum levels of matrix metalloproteinase 2 (MMP-2), 9 (MMP-9) and vascular endothelial growth factor (VEGF) were prospectively studied to confirm their utility in these two narrowly defined groups of cancer patients. Patients and Methods. The groups comprised 44 advanced HER2 BC, 24 CRPC patients and 42 healthy controls. An immunomagnetic separation method followed by PCR and electrophoretic detection (AdnaGen, Germany) were used for CTC determination. Serum marker levels were determined by the ELISAs (R&D System, USA). Results. MMP-2 serum level was significantly higher in HER2 BC patients who developed CNS metastases, especially if there were also bone metastases. CTCs were a negative predictive marker for overall survival in HER2 BC patients. MMP-9 serum level was significantly higher in CRPC patients in whom disease progression occurred. CTC vanished from the blood of most of the CRPC patients (from 88% to 37%) during chemotherapy. Conclusion. MMP-2 serum level and CTCs show the potential to predict CNS metastases and overall survival in BC patients. CTCs and MMP-9 serum level could be a promising therapy response marker in CRPC patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

Škereňová¹,

Mikulová²,

Čapoun³

et al. 2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…MMP1 is thus a major peptidase of the MMP family and plays a prominent role in collagen degradation, specifically that of collagen type I, which is important for remodeling of the extracellular matrix and cell-matrix interactions (18). The serum concentrations of MMP1, MMP3, and MMP9 have been found to be increased in patients with acute aortic dissection (19). Expression of MMP1 and MMP9 was also shown to be increased in tissue affected by aortic aneurysm or dissection (20).…”

Section: Discussionmentioning

confidence: 99%

Association of a matrix metallopeptidase 1 gene polymorphism with long-term outcome of thoracic aortic aneurysm

Kato

Tokuda²,

Inagaki³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Although genetic variants are thought to contribute to the development of thoracic aortic aneurysm including dissection (TAA), it remains unclear whether gene polymorphisms are associated with the long-term outcome of TAA. The purpose of the present study was to identify genetic variants associated with the long-term outcome of medically treated patients with TAA. A total of 103 medically-treated patients with TAA (13 aneurysms and 90 dissections) were retrospectively studied for their outcomes (mean follow-up period, 24 months). The genotypes for 95 polymorphisms of 89 candidate genes were determined by a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. Evaluation of genotype distributions by the Chi-square test and subsequent multivariable logistic regression analysis with adjustment for covariates revealed that the -340A→G polymorphism (rs514921) of the matrix metallopeptidase 1 gene (MMP1) was significantly (P=0.0288) associated with the outcome of TAA, with the minor G allele being related to a favorable outcome. The aneurysm diameter was significantly (P=0.0167) smaller in the combined group of the AG and GG genotypes for this polymorphism than in subjects with the AA genotype. Kaplan-Meier survival curves constructed according to MMP1 genotypes showed a more favorable outcome of TAA (log-rank P=0.0146) in subjects with the G allele of rs514921. Determination of genotype for this polymorphism may prove informative for assessment of the long-term outcome of TAA. IntroductionThoracic aortic aneurysm including dissection (TAA) is a serious condition that results from aortic atherosclerosis and is a leading cause of mortality (1). Recent studies on the genetic basis of familial TAA have focused on its relation to systemic connective tissue disorders such as the Marfan syndrome (2) and the Ehlers-Danlos syndrome (3). However, up to 19% of individuals with non-syndromic TAA referred for surgery have been found to have affected first-degree relatives (4). In addition to conventional risk factors for TAA including age, arteriosclerosis, hypertension, and inflammatory or autoimmune diseases, genetic epidemiological studies have suggested that genetic variants contribute to the initiation and progression of this condition (5,6). It has remained unclear, however, whether gene polymorphisms are associated with the long-term outcome of TAA.Although computed tomography (7) parameters are currently applied to prediction of the risk for TAA rupture, only the relative, not the individual, rupture risk can be determined (8). The identification of gene polymorphisms related to the long-term outcome of medically-treated TAA may therefore lead to a better understanding of the factors relevant to the progression and rupture of TAA, and consequently may better inform the selection of patients as candidates for surgical therapy because of a higher risk of rupture.We have now performed an association study for 95 polymorphisms of 89 candidat...

show abstract

“…Circulating concentrations of several matrix metalloproteinase types seem to be elevated in patients with acute dissection. 22 However, previous reports are challenging to interpret because they generally had small sample sizes, sources of comparison/control patients were often not described, and analyses were conducted with descriptive statistical methods without adjustment for other factors. Nonetheless, our results, together with those of Shinohara et al, 21 support the concept that elevated concentrations of circulating macromolecules found in aortic ECM could serve as biomarkers of thoracic aortic dissection.…”

Section: Odds Ratio (Or)mentioning

confidence: 99%

“…Fourth, more sensitive fibrillin assays are not currently available. Development of highly sensitive assays allowing quantitation of a full range of concentrations, by guest on May 12, 2018 http://circres.ahajournals.org/ Downloaded from especially at the low end where we expect normal levels to occur, will be required to better discriminate aortic dissection from other causes of chest pain. Fifth, the source of microfibril fragments detected in this study is unknown.…”

Section: Odds Ratio (Or)mentioning

confidence: 99%

Thoracic Aortic Aneurysm Frequency and Dissection Are Associated With Fibrillin-1 Fragment Concentrations in Circulation

Marshall

Carlson

O’Malley

et al. 2013

Circulation Research

View full text Add to dashboard Cite

Rationale: Mutations in fibrillin-1 are associated with thoracic aortic aneurysm (TAA) in Marfan syndrome.Genome-wide association studies also implicate fibrillin-1 in sporadic TAA. Fragmentation of the aortic elastic lamellae is characteristic of TAA.Objective: Immunoassays were generated to test whether circulating fragments of fibrillin-1, or other microfibril fragments, are associated with TAA and dissection. Methods and Results:

show abstract

Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia

Cited by 39 publications

References 26 publications

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

Association of a matrix metallopeptidase 1 gene polymorphism with long-term outcome of thoracic aortic aneurysm

Thoracic Aortic Aneurysm Frequency and Dissection Are Associated With Fibrillin-1 Fragment Concentrations in Circulation

Contact Info

Product

Resources

About